Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life CyclePaola Favuzza, Alan F. Cowman, Brad E. Sleebs et al.|Cell Host & Microbe|2020Cited by 167
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect micePhillip Pymm, Wai‐Hong Tham, Amy Adair et al.|Proceedings of the National Academy of Sciences|2021Cited by 165
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainAdam K. Wheatley, Wai‐Hong Tham, Phillip Pymm et al.|Cell Reports|2021Cited by 80
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivaxAnthony N. Hodder, Alan F. Cowman, Janni Christensen et al.|Structure|2022Cited by 32
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2Phillip Pymm, Nicholas A. Gherardin, Samuel J. Redmond et al.|iScience|2022Cited by 19